Рет қаралды 13,002
The ability of human cochlear hair cells to regenerate has been nothing more than a pipe dream - until recently. Frequency Therapeutics, a publicly traded (NASDAQ) company based in Lexington, Massachusetts, has published a series of clinical trials showing early promise that a pharmacologic agent, FX-322, regenerates human hair cells in the cochlea.
During this interview Franck and LeBel review biology of progenitor cells, their published clinical trials data and current status of a larger, blinded placebo control trial.
Results of the published trial, discussed in the interview, can be found at this link: journals.lww.com/otology-neur...
Transcript available: hearinghealthmatters.org/this...
Be sure to subscribe to our KZfaq channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and Twitter:
/ this-week-in-hearing
/ weekinhearing
Prefer to listen on the go? Tune into the TWIH Podcast on your favorite podcast streaming service, including Apple, Spotify, Google and more.
anchor.fm/thisweekinhearing
TIMESTAMP
00:00 Introduction
03:40 How does FX-322 work?
07:11 How does FX-322 get into the cochlea?
10:13 Published data on FX-322 effectiveness
14:09 FX-322-208 clinical trial
20:27 FX-322 in future practice